Karin Hoogendoorn – Decentralized Cell Therapy Manufacturing

On June 3rd, ATMP Sweden was joined in an insightful webinar featuring Karin Hoogendoorn, an expert in ATMPs and viral vector-based vaccines.

With over 25 years of experience spanning the pharmaceutical industry and academia, Karin has played key roles in chemical, manufacturing, and controls (CMC) and CMC- regulatory affairs across the full lifecycle of ATMP development. Currently serving as CMC leader oncology at Galapagos BV, she brings a wealth of knowledge on CMC, including manufacturing strategies for cell and gene therapy products. Karin will discuss considerations around decentralized manufacturing and testing models for cell therapy products, with attention to the unique challenges posed by working with fresh, non-cryopreserved materials.

We were also joined by Kerstin Sollerbrant who moderated the session. Kerstin is Senior Expert at The Swedish Childhood Cancer Fund and a patient representative in EMA’s Committee for Advanced Therapies, advocating for patient-centric innovation in ATMPs.

ATMP Sweden is a national coordination and communication network dedicated to accelerating patient access to innovative Advanced Therapy Medicinal Products (ATMPs) in Sweden. By connecting stakeholders, supporting regulatory processes, and hosting key events, we aim to support Sweden in becoming a world leader in ATMPs by 2030.